MARITIME-2

Official Title

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)

You can join if...

Inclusion Criteria:

1. Age greater than or equal to 18 years.
2. Body mass index greater than or equal to 27 kg/m^2.
3. History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
4. Diagnosis of T2DM.

Exclusion Criteria:

1. Type 1 diabetes mellitus.
2. Self-reported change in body weight greater than 5 kg within 90 days before screening.
3. Proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment.
4. Obesity induced by other endocrinologic disorders.
5. Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
6. History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.
7. History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.
8. Lifetime history of suicide attempt.